Growth funding Saluda Medical has completed a substantial funding and IPO trajectory, with a recent $230M financing and a public listing, indicating strong capital availability for scaling sales efforts, geographic expansion, and clinical adoption programs.

Global expansion Recent US launch of EVA sensing technology and Evoke SmartLoop integration, combined with ASX-listed growth, suggests opportunities to partner with hospital systems and specialists in chronic pain, neuromodulation, and spine centers across major markets.

Clinical momentum Continuous data-driven therapy with ECAP-controlled closed-loop SCS positions Saluda as a leader in personalized pain management, creating cross-sell opportunities with neuromodulation clinics, pain management groups, and surgeon-led pain programs.

Strategic partnerships Integration capabilities with existing tech stacks (WordPress, Salesforce, Azure AD, VMware) and emphasis on real-time data suggests collaboration potential with health IT platforms, clinical analytics providers, and patient engagement vendors to expand adoption and aftercare.

Market positioning Strong revenue growth signals demand in chronic pain management and neurostimulation, presenting targeted opportunities to approach hospital systems, distributors, and private clinics for system-wide deployments, training, and long-term service agreements.